keyword
MENU ▼
Read by QxMD icon Read
search

MAOI

keyword
https://www.readbyqxmd.com/read/29773358/-antidepressive-agents-and-hyponatremia-a-literature-review-and-a-case-non-case-study-in-the-french-pharmacovigilance-database
#1
Michaël Rochoy, Christina Zakhem-Stachera, Johana Béné, Christophe Berkhout, Sophie Gautier
OBJECTIVE: Most antidepressants have been associated with a risk of hyponatremia in the literature. This effect is not always reported in monographs. The aim of our study was to clarify the difference of increased risk of hyponatremia among various antidepressants. METHODS: Retrospective study of such cases/non-cases from observations recorded in the French national pharmacovigilance between 01/01/2004 and 31/12/2013. We studied all antidepressants marketed in 2014 in France, with a positive control (haloperidol) and a negative one (amoxicillin)...
March 1, 2018: Thérapie
https://www.readbyqxmd.com/read/29674970/hypothesis-the-psychedelic-ayahuasca-heals-traumatic-memories-via-a-sigma-1-receptor-mediated-epigenetic-mnemonic-process
#2
Antonio Inserra
Ayahuasca ingestion modulates brain activity, neurotransmission, gene expression and epigenetic regulation. N,N -Dimethyltryptamine (DMT, one of the alkaloids in Ayahuasca) activates sigma 1 receptor (SIGMAR1) and others. SIGMAR1 is a multi-faceted stress-responsive receptor which promotes cell survival, neuroprotection, neuroplasticity, and neuroimmunomodulation. Simultaneously, monoamine oxidase inhibitors (MAOIs) also present in Ayahuasca prevent the degradation of DMT. One peculiarity of SIGMAR1 activation and MAOI activity is the reversal of mnemonic deficits in pre-clinical models...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29620793/antidepressants-versus-placebo-for-panic-disorder-in-adults
#3
REVIEW
Irene Bighelli, Mariasole Castellazzi, Andrea Cipriani, Francesca Girlanda, Giuseppe Guaiana, Markus Koesters, Giulia Turrini, Toshi A Furukawa, Corrado Barbui
BACKGROUND: Panic disorder is characterised by repeated, unexpected panic attacks, which represent a discrete period of fear or anxiety that has a rapid onset, reaches a peak within 10 minutes, and in which at least four of 13 characteristic symptoms are experienced, including racing heart, chest pain, sweating, shaking, dizziness, flushing, stomach churning, faintness and breathlessness. It is common in the general population with a lifetime prevalence of 1% to 4%. The treatment of panic disorder includes psychological and pharmacological interventions...
April 5, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29596146/vortioxetine-disposition-in-obesity-potential-implications-for-patient-safety
#4
David J Greenblatt, Jerold S Harmatz, Christina R Chow
BACKGROUND: Obesity and depression are common comorbid conditions. The objective of the study was to evaluate the effect of obesity on the pharmacokinetics of the serotonergic antidepressant vortioxetine. METHODS: Vortioxetine pharmacokinetics were evaluated in 16 otherwise healthy obese volunteers (mean weight, 119 kg; mean body mass index (BMI) 41.8 kg/m) and in 14 normal-weight subjects (mean weight, 68 kg; mean BMI, 23.0 kg/m) matched for age. All subjects received a single 5-mg oral dose of vortioxetine once daily for 29 days...
March 28, 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29421700/synthesis-biological-evaluation-and-molecular-modeling-studies-of-phenyl-benzhydrylpiperazine-derivatives-as-potential-mao-inhibitors
#5
Bhupinder Kumar, Sheetal, Anil K Mantha, Vinod Kumar
Monoamine oxidase inhibitors (MAOIs) are potential drug candidates for the treatment of various neurological disorders like Parkinson's disease, Alzheimer's disease and depression. In the present study, two series of 4-substituted phenylpiperazine and 1-benzhydrylpiperazine (1-21) derivatives were synthesized and screened for their MAO-A and MAO-B inhibitory activity using Amplex Red assay. Most of the synthesized compounds were found selective for MAO-B isoform except compounds 3, 7, 8, 9 and 13 (MAO-A selective) while compound 11 was non-selective...
April 2018: Bioorganic Chemistry
https://www.readbyqxmd.com/read/29335210/privileged-scaffolds-as-mao-inhibitors-retrospect-and-prospects
#6
REVIEW
Avinash C Tripathi, Savita Upadhyay, Sarvesh Paliwal, Shailendra K Saraf
This review aims to be a comprehensive, authoritative, critical, and readable review of general interest to the medicinal chemistry community because it focuses on the pharmacological, chemical, structural and computational aspects of diverse chemical categories as monoamine oxidase inhibitors (MAOIs). Monoamine oxidases (MAOs), namely MAO-A and MAO-B represent an enormously valuable class of neuronal enzymes embodying neurobiological origin and functions, serving as potential therapeutic target in neuronal pharmacotherapy, and hence we have coined the term "Neurozymes" which is being introduced for the first time ever...
February 10, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29286588/epidemiology-and-economic-burden-of-serotonin-syndrome-with-concomitant-use-of-serotonergic-agents-a-retrospective-study-utilizing-two-large-us-claims-databases
#7
Charles T Nguyen, Lin Xie, Stephanie Alley, Robert M McCarron, Onur Baser, Zhixiao Wang
Objective: Serotonin syndrome (SS) is an adverse drug reaction occurring among patients receiving serotonergic agents (SAs), and although SAs are commonly prescribed, the epidemiology and economic burden of SS with concomitant SA use have not been comprehensively examined. The objective of this study was to investigate the prevalence, incidence, and economic burden of SS with SA use. Methods: A retrospective cohort study was conducted using Veterans Health Administration (VHA) records (identification period: October 1, 2008-September 30, 2012) and commercially insured patient records (Intercontinental Marketing Services PharMetrics Plus; identification period: January 1, 2010-December 31, 2013)...
December 28, 2017: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/29133700/wearing-off-a-complex-phenomenon-often-poorly-recognized-in-parkinson-s-disease-a-study-with-the-woq-19-questionnaire
#8
Michele Pistacchi, Manuela Gioulis, Flavio Sanson, Sandro Z Marsala
BACKGROUND: 'Wearing off' refers to the phenomenology of movement disorders in Parkinson's disease (PD) that appears early and is much commoner than generally believed. It may be present in the form of either motor symptoms or non-motor symptoms. AIM: To investigate the utility of wearing-off questionnaire (WOQ-19, Italian version) in the outpatient clinical practice to assess the suitability of different combinations of treatment, in various stages of PD. METHODS: 73 consecutive patients (58% male and 42% female) suffering from PD were recruited through the Santorso Hospital and San Martino Hospital from September 2012 to March 2014...
November 2017: Neurology India
https://www.readbyqxmd.com/read/29048739/pharmacotherapy-for-social-anxiety-disorder-sand
#9
REVIEW
Taryn Williams, Coenraad J Hattingh, Catherine M Kariuki, Sean A Tromp, Anton J van Balkom, Jonathan C Ipser, Dan J Stein
BACKGROUND: Recognition is growing that social anxiety disorder (SAnD) is a chronic and disabling disorder, and data from early trials demonstrate that medication may be effective in its treatment. This systematic review is an update of an earlier review of pharmacotherapy of SAnD. OBJECTIVES: To assess the effects of pharmacotherapy for social anxiety disorder in adults and identify which factors (methodological or clinical) predict response to treatment. SEARCH METHODS: We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR-Studies and CCMDCTR-References) to 17 August 2015...
October 19, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28971618/higher-patient-satisfaction-with-antidepressants-correlates-with-earlier-drug-release-dates-across-online-user-generated-medical-databases
#10
Scott Siskind, Roland C Aydin, Punit Matta, Christian J Cyron
Studies establishing the use of new antidepressants often rely simply on proving efficacy of a new compound, comparing against placebo and single compound. The advent of large online databases in which patients themselves rate drugs allows for a new Big Data-driven approach to compare the efficacy and patient satisfaction with sample sizes exceeding previous studies. Exemplifying this approach with antidepressants, we show that patient satisfaction with a drug anticorrelates with its release date with high significance, across different online user-driven databases...
October 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28948471/impact-of-socio-demographic-factors-on-the-mitigating-actions-for-climate-change-a-path-analysis-with-mediating-effects-of-attitudinal-variables
#11
Muhammad Mehedi Masud, Rulia Akhatr, Shamima Nasrin, Ibrahim Mohammed Adamu
Socio-demographic factors play a significant role in increasing the individual's climate change awareness and in setting a favorable individual attitude towards its mitigation. To better understand how the adversative effects of climate change can be mitigated, this study attempts to investigate the impact of socio-demographic factors on the mitigating actions of the individuals (MAOI) on climate change. Qualitative data were collected from a face-to-face survey of 360 respondents in the Kuala Lumpur region of Malaysia through a close-ended questionnaire...
December 2017: Environmental Science and Pollution Research International
https://www.readbyqxmd.com/read/28948135/pharmacological-management-of-anxiety-disorders-in-the-elderly
#12
Elizabeth A Crocco, Sindy Jaramillo, Caroline Cruz-Ortiz, Katherine Camfield
Anxiety disorders are common in the elderly. Additionally, anxiety symptoms often accompany co-morbid psychiatric, medical, as well as neurodegenerative diseases in the older population. Anxiety in the elderly, often accompanied by depression, can lead to worsening physical, cognitive and functional impairments in this vulnerable population. Antidepressants are considered first line treatment. Both SSRIs and SNRIs are efficacious and well-tolerated in the elderly. Some SSRIs are strong inhibitors of the cytochrome P450 hepatic pathway whereas others have less potential for drug interaction...
March 2017: Current Treatment Options in Psychiatry
https://www.readbyqxmd.com/read/28743448/chronic-cb1-cannabinoid-receptor-antagonism-persistently-increases-dendritic-spine-densities-in-brain-regions-important-to-zebra-finch-vocal-learning-and-production-in-an-antidepressant-sensitive-manner
#13
Tessa L Holland, Ken Soderstrom
During typical late-postnatal CNS development, net reductions in dendritic spine densities are associated with activity-dependent learning. Prior results showed agonist exposure in young animals increased spine densities in a subset of song regions while adult exposures did not, suggesting endocannabinoid signaling regulates dendritic spine dynamics important to vocal development. Here we addressed this question using the CB1 receptor-selective antagonist SR141716A (SR) to disrupt endocannabinoid signaling both during and after vocal learning...
October 1, 2017: Brain Research
https://www.readbyqxmd.com/read/28705604/major-depression-and-heart-failure-interest-of-monoamine-oxidase-inhibitors
#14
REVIEW
Sophie Corbineau, Marie Breton, Jeanne Mialet-Perez, Jean-François Costemale-Lacoste
Several physiopathological hypotheses have been studied to explain the link between heart failure (HF) and major depression (MD). An increase of monoamine oxidase (MAO) has recently been found as a factor involved in the development of HF. The aim of this review is to provide a complete overview of the involvement of MAOs in HF comorbidity of MD and to discuss the pharmacological options. Our work highlights the scientific evidence of MAO involvement in the development of HF. Studies focusing on MAO-A seem to have reproducible results on HF, establishing the effect of this enzyme as well as the protective effect of its inhibition...
November 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28562526/efficacy-of-antidepressive-medication-for-depression-in-parkinson-disease-a-network-meta-analysis
#15
REVIEW
Chuanjun Zhuo, Rong Xue, Lanlan Luo, Feng Ji, Hongjun Tian, Hongru Qu, Xiaodong Lin, Ronghuan Jiang, Ran Tao
BACKGROUND: Parkinson disease (PD) was considered as the 2nd most prevalent neurodegenerative disorder after Alzheimer disease, while depression is a prevailing nonmotor symptom of PD. Typically used antidepression medication includes tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI), monoamine-oxidase inhibitors (MAOI), and dopamine agonists (DA). Our study aimed at evaluating the efficacy of antidepressive medications for depression of PD...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28514974/additional-thoughts-on-teaching-and-prescribing-maois
#16
S Shalom Feinberg
No abstract text is available yet for this article.
October 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28413973/docking-related-survey-on-natural-product-based-new-monoamine-oxidase-inhibitors-and-their-therapeutic-potential
#17
REVIEW
Priyanka Dhiman, Neelam Malik, Anurag Khatkar
BACKGROUND: This is an exciting period for research on monoamine oxidase and its effects on central nervous system. As the current hitting-one-target, therapeutic strategy has become quite inefficient for the treatment of various neurological disorders Objective: The objective of this review is to identify and critically discuss the computational development of multi-target natural and related ligand-MAO protein docking approaches in the study of monoamine oxidase (MAO) enzymes. DISCUSSION: Computational development of the new compounds from natural and related synthetic origin, active as MAO inhibitors (MAOIs) was discussed in some detail...
2017: Combinatorial Chemistry & High Throughput Screening
https://www.readbyqxmd.com/read/28384235/risk-analysis-of-use-of-different-classes-of-antidepressants-on-subsequent-dementia-a-nationwide-cohort-study-in-taiwan
#18
Chee-Kin Then, Nai-Fang Chi, Kuo-Hsuan Chung, Lynn Kuo, Kao-Hui Liu, Chaur-Jong Hu, Shing-Chuan Shen, Yen-Kuang Lin
Depression and dementia are common mental health problems and are associated in several ways. Early-life depression is associated with increased risk of later life dementia, and depression can present as a preclinical symptom or consequence of dementia. Despite the plausible relationship between these two clinical entities, the potential association between antidepressant medication and dementia has rarely been investigated. We conducted a 9-year retrospective analysis of Taiwan's National Health Insurance Research Database (NHIRD), enrolling 5819 cases who had received prescriptions of antidepressants between 2003 and 2006, and 23,276 (with ratio of 1:4) age, sex, and index date-matched controls...
2017: PloS One
https://www.readbyqxmd.com/read/28378157/adherence-and-persistence-across-antidepressant-therapeutic-classes-a-retrospective-claims-analysis-among-insured-us-patients-with-major-depressive-disorder-mdd
#19
Katelyn R Keyloun, Ryan N Hansen, Zsolt Hepp, Patrick Gillard, Michael E Thase, Emily Beth Devine
BACKGROUND: Adherence and persistence to therapy, or how well a patient follows provider directions on frequency and time to discontinuation of prescribed medications, is associated with positive health outcomes, including decreased healthcare costs and patient mortality. A clear literature gap exists assessing adherence and persistence to antidepressants (ADs) in the major depressive disorder (MDD) population at clinically relevant time points and at the therapeutic class level. OBJECTIVE: This study assessed adherence and persistence to specific ADs, therapeutic classes, and AD therapy overall at multiple time points among US individuals from commercial, Medicare supplemental, and Medicaid insurance plans...
May 2017: CNS Drugs
https://www.readbyqxmd.com/read/28004621/augmentation-of-phenelzine-with-aripiprazole-and-quetiapine-in-a-treatment-resistant-patient-with-psychotic-unipolar-depression-case-report-and-literature-review
#20
Jonathan M Meyer, Michael A Cummings, George Proctor
Irreversible monoamine oxidase inhibitor (MAOI) antidepressants have significant efficacy in treatment-resistant unipolar depression, but in some instances patients may not achieve remission. Among the adjunctive and augmentation strategies, certain second-generation antipsychotics (SGAs) have approval for inadequate responders to antidepressant therapy, including aripiprazole, brexpiprazole, and quetiapine, with lurasidone and the olanzapine/fluoxetine combination indicated for bipolar depression. Clinicians may eschew SGA options in part due to the limited literature on SGA-MAOI combinations, with only one published case involving aripiprazole, and none for olanzapine, lurasidone, or brexpiprazole...
October 2017: CNS Spectrums
keyword
keyword
12097
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"